Barclays Maintains Overweight on Hilton Worldwide Holdings, Raises Price Target to $384
Barclays analyst Brandt Montour maintains Hilton Worldwide Holdings (NYSE:HLT) with a Overweight and raises the price target from $368 to $384.
Stocks · News reference
A Congress Member Sold Up To $15K In Viasat Stock: Here's What You Need To Know
A September filing shows that Representative Jonathan Jackson reported a sale in Viasat (NASDAQ:VSAT), valued between $1,001 and $15,000. The transaction date is listed as August 28, 2026, with the report published on
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of travel and hotel companies are trading higher as bond yields retreat, with investors rotating out of AI-exposed stocks to sectors with more proven cash flows ahead of continued Fed monetary tightening.
Morgan Stanley Maintains Overweight on Hilton Worldwide Holdings, Raises Price Target to $336
Morgan Stanley analyst Stephen Grambling maintains Hilton Worldwide Holdings (NYSE:HLT) with a Overweight and raises the price target from $332 to $336.
Hotel Leaders Take Center Stage at The Hospitality Show 2026
The Hospitality Show has unveiled its 2026 Center Stage program featuring eight sessions scheduled for November 3-4 in Miami Beach. The event will bring together hotel executives and industry leaders to discuss guest loyalty, profitability, AI implementation, food and beverage optimization, workforce development, and management fee value. Notable speakers include executives from Wyndham Hotels & Resorts, Hilton, Sandals Resorts International, and other major hospitality companies.
UBS Maintains Buy on McKesson, Raises Price Target to $1200
UBS analyst Kevin Caliendo maintains McKesson (NYSE:MCK) with a Buy and raises the price target from $1080 to $1200.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.